Oncopeptides AB (publ) (ONPPF) Stock Price, News & Analysis

Company Overview

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden

Key Stats

• Today's Range: $0.27 to $0.27
• 50-Day Range: $0.27 to $0.27
• 52-Week Range: $0.27 to $0.27
• Volume: N/A
• Average Volume: 2,250 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ONPPF Stock Analysis - Frequently Asked Questions

How have ONPPF shares performed this year?

Oncopeptides AB (publ)'s stock was trading at $0.2650 at the start of the year. Since then, ONPPF shares have increased by 0.0% and is now trading at $0.2650.
View the best growth stocks for 2025 here.

How do I buy shares of Oncopeptides AB (publ)?

Shares of ONPPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTC
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTC:ONPPF
• CIK: N/A
• Web: www.oncopeptides.se
• Phone: 46 86 15 20 40
• Fax: N/A
• Employees: 67
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A